A perspective on the trade-offs between safety & efficacy in 1st line RCC

A perspective on the trade-offs between safety & efficacy in 1st line RCC

User Photo
obr

2 years
124 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the 2018 Annual Meeting.
Up Next Autoplay